When an actively growing culture of the H37Ra strain of Mycobacterium tuberculosis was exposed to isoniazid at a concentration of 0.5 ,g/ml, the cells began to lose their ability to synthesize mycolic acids immediately. After 60 min, the cells had completely lost this ability. The synthesis of the three mycolate components-amycolate, methoxymycolate, and f-mycolate-was inhibited. The viability of the isoniazid-treated cells was unaffected up to about 60 min of exposure, after which time there was a gradual decline in the viability to about 18% after 180 min. Correspondingly, growth of the drug-treated cells slowed down and stopped after 24 hr. The inhibition of the synthesis of mycolic acids was reversible if the drug was removed before the loss of viability set in. Incubation of the viable cells in the absence of the drug for 24 hr restored the mycolate synthesis. These results strongly suggest that the inhibition of the synthesis of the mycolic acids is closely associated with the primary mechanism of action of isoniazid on the tubercle bacilli. The sequence of events which leads to the loss of viability of cells exposed to isoniazid is described.
Isoniazid is the mainstay of antituberculosis therapy. Since its discovery as a tuberculostatic agent (12) , much work has been done to elucidate its mechanism of action (32) . The precise nature of the primary action of isoniazid on the tubercle bacilli is unknown today.
One of the more significant early observations was that tubercle bacilli lose their acid-fastness when exposed to isoniazid (14) , suggesting that the composition of a certain lipid might be somewhat altered. The altered component could be the mycolic acids which have been implicated in the acidfastness of this organism (11) . Studies of several workers suggested an intimate relationship between the effect of the drug and the synthesis of specific lipid components unique to the cell envelope of the tubercle bacilli (4, 10, 25, 26) . Recently, Winder and associates found evidence that isoniazid interfered with the formation of the cell envelope, specifically the synthesis of mycolic acids (30, 31) .
We have investigated the effect of isoniazid on the in vivo synthesis of mycolic acids in M. tuberculosis H37Ra using '4C-acetate as the metabolite. We found that isonizaid at a concentration of 0.5 pg/ml immediately began to reduce the cells' ability to synthesize mycolic acids. The gradual decline in viability of the cells began only after complete inhibition of the synthesis of mycolic acids had occurred. In addition, the effect of the drug on the synthesis of mycolates was reversible if the drug was removed before the cells lost their viability. These findings are used to describe the possible mechanism of the action of isoniazid.
MATERLALS AND METHODS
Bacterial strain and growth. M. tuberculosis H37Ra was grown in either (A) glycerol-alanine-salts medium or (B) the Middlebrook 7H9 medium (Difco) with Tween 80 and ADC enrichment in a rotary shaker at 37 C. Medium B was used when quantitative sampling of the culture was required. Because of the dispersed growth in the latter medium, growth could be followed by measuring the absorbancy at 650 nm with a Coleman spectrophotometer model 6/20 and was extracted with a total of 12 ml ofdiethyl ether. The ether extract was evaporated to dryness, and onetenth of the sample was used to assay for total radioactivity. Carrier mycolic acids (100,g) were added to the remaining extract, and were methylated with diazomethane. The entire methylated mycolate sample was applied to a Silica Gel G thin-layer plate and developed with solvent III. The methyl mycolate spots were located with iodine spray and analyzed for radioactivity as described. (8), Etamadi and Lederer (9) , and Minnikin and Polgar (19) (20) (21) (22) for the mycolic acids of the tubercle bacilli. The first group concluded that there were two homologue series of mycolic acids (A and B). The point of controversy is the homologue series A, which appears to be related to $B-mycolate, in that both show a keto functional group. However, the homologues of series A have neither the methylene side chain nor the cyclopropane ring present in $-mycolate. In place of the cyclopropane ring, the series A compounds contain a double bond. For this reason, we have reinvestigated the structure of the mycolic acids in the H37Ra strain. In addition, we desired to separate each of the several mycolate components and identify them so that we could measure the effects of isoniazid on each mycolic acid component.
The bound lipids were extracted from 7.8 g of crude cell wall preparation of the H37Ra strain, methylated, and then fractionated on a silicic acid column as previously described (1) to obtain the crude methyl mycolate fraction. The Sephadex LH-20 column fractionation yielded 132.5 mg of partially purified methyl mycolate. This sample was then further fractionated into three major mycolate components by Silica Gel G thin-layer chromatography in solvents I and II (developed twice). By infrared, nuclear magnetic resonance, and mass spectral analysis, the three components were identified as follows (in the order of decreasing RF values): a-mycolate, 70.2 mg (melting point, 49 to 50 C); methoxymycolate, 5.9 mg (melting point, 42.5 C);
and fi-mycolate, 1.6 mg (melting point, 45 C).
The total recovery of the methyl mycolates was 59%. These results correspond to the published data on the identity of major mycolate components of tubercle bacilli (8, 9, (19) (20) (21) (22) . The difference between our results and those obtained previously (1) on the structure of mycolic acids in the H37Ra strain can probably be attributed to the fact that other investigators attempted to determine the structural components by interpret- a To three flasks (80 ml) of 9-day-old cells of M. tuberculosis grown in medium A, 5 ,uCi of radioactive metabolite per flask was added and incubated for 17 hr on a shaker at 37 C. The cells were harvested by filtration and washed with water. The ether extracts from the saponified and acidified cells were further fractionated by an ethanol-ether extraction to obtain the "4C-mycolic acids. A sample of the labeled mycolic acids (4,500 counts/min plus 100 Lg of carrier mycolic acids) was methylated and then fractionated by two-dimensional thin-layer chromatography to yield the three components. Radioactivity in each component was determined and the percent distribution was calculated.
ing the mass spectra of a partially purified mixture of the methyl mycolates.
Determination of a suitable labeled metabolite to use in measuring mycolate synthesis. For our studies into the effects of isoniazid on the synthesis of mycolic acids in the tubercle bacilli, we needed to determine the most appropriate labeled metabolite to use in measuring the in vivo synthesis. We Fig. I were isolated and purified by thin-layer chromatography. They were separated into the three components and their specific radioactivities were determined.
An experiment was performed to determine whether isoniazid inhibits the synthesis of the mycolic acids. Figure 1 shows that, when isoniazid was added at a concentration of 0.5 jug/ml, the incorporation of 14C-acetate into the total mycolate fraction was drastically inhibited. This figure also shows that the drug did not inhibit the incorporation of '4C-acetate into the normal fatty acids. Table 2 shows that the synthesis of all three components of mycolic acids was inhibited to the extent of 78 %.
A similar experiment was performed to determine the effect of isoniazid on the incorporation of the tritiated methyl group from L-[methyl-3H]-methionine into the mycolic acids. Whereas the label from 'IC-acetate would be expected to become evenly distributed throughout the mycolate molecules, the tritium in the CH3 group of L-methionine can be incorporated into the methylene side chain (2, 16) and the cyclopropane ring (5, 33) of the mycolates. Since the points of entry of these two metabolites into the pathway for the synthesis of mycolic acids differ, they represent two types of assays for mycolate synthesis. The results of such an experiment showed that again isoniazid inhibited the synthesis of the mycolic acids (Fig. 2) .
Effect of isoniazid concentration on mycolic acid synthesis. To 10-ml tube cultures of M. tuberculosis grown in medium B with shaking, different amounts of isoniazid were added, and the cultures were incubated for 1 hr. The cultures were assayed immediately for their ability to synthesize the mycolates. Figure 3 shows that mycolic acid synthesis decreased nonlinearly with increasing concentration of isoniazid. Under the assay conditions used, the inhibition approached completion at a drug concentration of about 0.5 ,g/ml. We thus chose this threshold concentration for all subsequent experiments. Isoniazid has been reported to inhibit the incorporation of 'IC-acetate into mycobacteria (7, 29) . A close examination of Wimpenney's data (29) reveals that the uptake of '4C-acetate in a 14-to 21-day surface culture of M. tuberculosis BCG containing isoniazid at a concentration of 10 ,ug/ml is slightly lower than in the control after 15 min. In our assay for mycolate synthesis, we detected no inhibition of the uptake and the incorporation of 'IC-acetate into the total lipids of M. tuberculosis in the presence of isoniazid in the concentration range of 0.10 to 1.00 Ag/ml. tuberculosis incubated in the absence (A) and presence (B) of isoniazid. The detailed procedure for this experiment is identical to that in Fig. 1 Fig. 4 , the ability of the cells to incorporate labeled acetate into the mycolic acids decreased linearly with time of exposure; after 60 min, the activity was measured to be 1 . The growth of both the isoniazidtreated and the control cultures was followed simultaneously by measuring their absorbancy at 650 nm. We found that isoniazid-treated cultures continued to increase in absorbancy for 24 hr before leveling off. This is consistent with published observations (3, 17, 18) . After the loss of mycolate synthesis, the viability of these isoniazid-treated cells remained unaffected for about 30 min (Fig. 4) . A statistically significant drop in the number of viable cells occurred after 90 min of exposure to the drug. After 180 min, the population of viable cells was reduced to 18%(o.
Restoration of mycolic acid synthesis in washed cells of M. tuberculosis after exposure to isoniazid. Since there seemed to be an apparent lag between the time of complete inhibition of mycolate synthesis (60 min) and the beginning of the statistically significant decrease in cell viability (90 min) when the tubercle bacillus was exposed to 0.5 ,g of isoniazid/ml, we proceeded to investigate the possibility of reversing the inhibition of mycolate synthesis. Table 3 shows that, as before, the cells exposed to isoniazid for 60 min had a greatly reduced ability to synthesize mycolates. In a separate experiment, we found that when such isoniazid-treated cells were washed free from the drug and assayed immediately, the cells were unable to synthesize the mycolic acids. However, when these washed cells were reincubated in a fresh medium for 24 or 48 hr, as shown in Table 3 , they recovered their ability to synthesize the mycolates. In these experiments, the washed and reincubated cells continued to grow normally for at least three generation times, showing a typical growth curve for M. tuberculosis. The cells that were left to grow in the original culture medium containing isoniazid showed the usual growth inhibition after 24 In experiment I, the cells were exposed to isoniazid at 0.5 jg/ml for 60 min. Samples (10 ml) were transferred into sterile tubes, centrifuged, and washed three times with sterile medium at 0 C under aseptic conditions. The cells were then resuspended in 5 inhibition of the synthesis of these lipids after exposing an actively growing culture to 0.5 Ag of the drug per ml. All three components of the mycolic acids were similarly inhibited. It is interesting to note that the time required for the cells' complete loss of mycolate synthesis (60 min) coincided with the extrapolated beginning of the decline in the viability of the cells.
The level of the drug used (0.5 Ag/ml) approaches the minimal inhibitory concentration for growth, viability, and mycolate synthesis. These observations, together with the facts that the M. tuberculosis cells contain their own unique forms of mycolic acids (15) and are highly sensitive to isoniazid (23, 27) , suggest that a close relationship exists between the synthesis of these specific lipids and the viability and growth of the cells.
Our observation of the immediate inhibition of the synthesis of mycolic acid is, of course, the earliest event ever reported. Previously, the effect of the drug was examined several hours and even days after its addition. Other effects of isoniazid reported to occur within 60 min were the uptake of the drug, its metabolism, and the formation of pigments (32) . In the recent work of Winder and Colfins (30) , in which they used "4C-glycerol as the metabolite, the minimal exposure time was 3 hr. Virtually all othei studies done on the tubercle bacilli at threshold levels of the drug used exposure times of at least 24 hr (32) .
The order of action of isoniazid on M. tuberculosis can be described as follows. Cells exposed to 0.5 Mig of isoniazid/ml gradually lose their ability to synthesize mycolic acids, until a complete loss occurs after about 60 min. At this point, the cells slowly begin to lose their viability so that, after an additional 120 min, 80% of the cells are nonviable. Thus, there is a certain period of time (up to about 2 hr) when the cells continue to grow in the absence of mycolate synthesis and still maintain their viability. Also within this period, it is apparent that the complete inhibition in the in vivo synthesis of mycolic acid is slowly reversible by simply removing the drug and reincubating in fresh medium. The action of the isoniazid on the mycolate synthesis mechanism is immediate. The reaction of the mycolate-synthesizing system to the drug in vivo is a gradual response. The lethal event appears to develop even more gradually.
One can perhaps describe the lethal action of the drug in the following manner. A certain critical point is reached in the growth of a bacillus when, owing to the lack of mycolic acids in the newly developed cell wall and envelope, the cells are irreversibly damaged and cannot perform the function of dividing. Perhaps we can call this a form of "unbalanced growth," which eventually becomes lethal after a definite exposure time that we can predict to be a fraction of a generation time. A similar conclusion was reached by Winder and Collins (30) . The concept that the bactericidal effects of a drug are produced by an imbalance in the synthesis of cellular constituents has considerable experimental support (26) .
The key question to be asked is, how does isoniazid inhibit mycolate synthesis? Since the action is immediate, we would expect the drug to act directly on the system at the transcription or translation level, or on the enzyme(s) of the pathway of mycolate synthesis. A clue may be provided by the work of Gangadharam et al.
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on October 26, 2017 by guest http://aac.asm.org/ Downloaded from (13) . When one extrapolates their data to less than 3 hr of exposure to isoniazid, it shows that both total protein and ribonucleic acid synthesis are unaffected, whereas deoxyribonucleic acid synthesis may be inhibited by isoniazid. They suggested this to be analogous to the lethal "unbalanced growth" of the thymineless mutants of Escherichia coli during thymine starvation (6) . We are presently investigating this possibility.
